GSE113369 p53 inhibition 2 v 4 human dn (Gene Set)

Analyze

Playbook Workflow Builder
Playbook Workflow Builder: Gene Set Enrichment

Perform Gene Set Enrichment with this gene set against Common Fund program's gene sets, identifying significant overlaps using a pre-built PWB workflow. Run the workflow with GSE113369_p53 inhibition_2_v_4_human_dn.

GeneSetCart
GeneSetCart

GeneSetCart helps you to fetch gene sets from various data sources, augment, combine with set operations, visualize and analyze these gene sets in a single session. Start a new session with GSE113369_p53 inhibition_2_v_4_human_dn.

CFDE-GSE
CFDE Gene Set Enrichment (GSE)

CFDE-GSE illuminates connections between the input gene set and various CF gene sets that overlap with the queried gene set. Query CFDE-GSE with GSE113369_p53 inhibition_2_v_4_human_dn.

Playbook Workflow Builder
Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with GSE113369_p53 inhibition_2_v_4_human_dn.

Results found

Linked to

 

Label

Description

 

Gene

high mobility group box 1 pseudogene 5

Gene

long intergenic non-protein coding RNA 3219

Gene

ZFHX3 antisense RNA 1

Gene

L-threonine dehydrogenase (pseudogene)

Gene

Rho GTPase activating protein 11B

Gene

PPP1R35 antisense RNA 1

Gene

FANCD2 pseudogene 2

Gene

centromere protein K

Gene

coiled-coil domain containing 18

Gene

leucine rich repeat and coiled-coil centrosomal protein 1

  • Gene

    high mobility group box 1 pseudogene 5


  • Gene

    long intergenic non-protein coding RNA 3219


  • Gene

    ZFHX3 antisense RNA 1


  • Gene

    L-threonine dehydrogenase (pseudogene)


  • Gene

    Rho GTPase activating protein 11B


  • Gene

    PPP1R35 antisense RNA 1


  • Gene

    FANCD2 pseudogene 2


  • Gene

    centromere protein K


  • Gene

    coiled-coil domain containing 18


  • Gene

    leucine rich repeat and coiled-coil centrosomal protein 1

  • DISPLAY PER PAGE
    This repository is under review for potential modification in compliance with Administration directives.